Deitelzweig S, Keshishian A, Kang A, Dhamane AD, Luo X, Li X, Balachander N, Rosenblatt L, Mardekian J, Pan X, Fusco, MD, Garcia Reeves AB, Yuce H, and Lip GYH.

Objective: To investigate the effectiveness and safety of NOACs (apixaban, dabigatran, and rivaroxaban) and warfarin in obese patients (defined using diagnosis codes indicating obesity or BMI ≥30 kg/m²)